SWK Holdings Corp
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
SWKHL$25.21+0.1%Stored close · as of Nov 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income
(In thousands, except per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues: | ||
| Finance receivable interest income, including fees | $36,346 | $35,461 |
| Pharmaceutical development | 1,202 | 5,485 |
| Other | 212 | 538 |
| Total revenues | 37,760 | 41,484 |
| Costs and expenses: | ||
| Allowance for credit losses | 1,912 | 3,491 |
| Impairment of goodwill | 8,404 | — |
| Interest expense | 1,849 | 340 |
| Pharmaceutical manufacturing, research and development expense | 3,436 | 6,952 |
| General and administrative | 11,232 | 12,964 |
| Change in fair value of acquisition-related contingent consideration | (6,300) | 5,170 |
| Depreciation and amortization expense | 2,577 | 2,599 |
| Income from operations | 14,650 | 9,968 |
| Other income (expense), net | ||
| Unrealized net (loss) gain on warrants | (55) | 417 |
| Unrealized net loss on equity securities | — | (528) |
| Realized loss from sale of investments | (799) | (151) |
| Foreign currency transaction gain (loss) | 817 | (215) |
| Income before income tax benefit | 14,613 | 9,491 |
| Income tax benefit | (1,274) | (4,000) |
| Net income | $15,887 | $13,491 |
| Net income per share | ||
| Basic | $1.26 | $1.05 |
| Diluted | $1.25 | $1.05 |
| Weighted average shares outstanding | ||
| Basic | 12,653 | 12,835 |
| Diluted | 12,696 | 12,880 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.